Mackenzie Financial Corp Makes New Investment in Genmab A/S (NASDAQ:GMAB)

Mackenzie Financial Corp purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,010 shares of the company's stock, valued at approximately $689,000.

Several other institutional investors also recently modified their holdings of GMAB. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its position in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares in the last quarter. Barclays PLC grew its position in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Cromwell Holdings LLC grew its position in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Genmab A/S during the 4th quarter worth approximately $60,000. Institutional investors own 7.07% of the company's stock.

Analysts Set New Price Targets

GMAB has been the topic of several research analyst reports. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research report on Thursday, February 13th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Trading Up 0.1%

Genmab A/S stock traded up $0.03 on Thursday, reaching $21.81. 680,200 shares of the stock were exchanged, compared to its average volume of 1,154,437. The stock has a market cap of $13.98 billion, a PE ratio of 12.53, a PEG ratio of 2.65 and a beta of 0.96. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56. The firm has a fifty day moving average price of $20.06 and a two-hundred day moving average price of $20.66.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.